Clinical trials: Multiple Sclerosis Relapse, open to volunteers
Relapsing Multiple Sclerosis
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to…
- Trial name
- NCT07220252
- Testing
- Ublituximab, Fingolimod
- Where
- 6 sites in United States, Poland and 1 more
- Volunteers
- 240 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Depression - Major Depressive Disorder
Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis
Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue.
- Conditions
- Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue
- Trial name
- NCT07562074
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Multiple Sclerosis, Functional Neurological Disorders
Bridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that may cause a broad range of motor and non-motor symptoms.
- Trial name
- NCT07856485
- Testing
- Functional Motor Disorder-Specific Multidisciplinary Rehabilitation, Conventional Multiple Sclerosis Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 192 people
- Sponsor
- IRCCS San Raffaele
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis.
- Trial name
- NCT07827716
- Testing
- Terfenadine, Standard First-line Disease-Modifying Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuan Qin
Multiple Sclerosis, Disease Management
Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis
This study aims to evaluate a questionnaire used by a specialized nurse to help manage relapses in people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Disease Management, Feasibility Studies
- Trial name
- NCT06994026
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Gonesse
Multiple Sclerosis
Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.
- Trial name
- NCT05748015
- Testing
- quantification of sensory and autonomic small nerve fibers by punch skin biopsy, Cardiovascular Reflexes testing, Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
- Trial name
- MUSCAT (NCT07321093)
- Testing
- BCD-281, Ocrelizumab
- Where
- Russia
- Volunteers
- 292 people
- Sponsor
- Biocad
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
- Trial name
- ENABLE (NCT06433752)
- Testing
- No Intervention
- Where
- 113 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,000 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
- Trial name
- NCT05964829
- Testing
- Cionic Neural Sleeve NS-100, Walking Program
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cionic, Inc.
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Multiple Sclerosis
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.
- Trial name
- SPRING (NCT04480853)
- Testing
- Fingolimod
- Where
- 6 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis (RRMS)
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage.
- Trial name
- TWINS (NCT06663189)
- Testing
- treatment withdrawal, Usual DMT continuation, MRI
- Where
- 22 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis.
- Trial name
- MS-ACT (NCT06567197)
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body.
- Trial name
- NCT07826689
- Testing
- PRO-1562 Oral Capsules
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Progentos Therapeutics
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
This pilot mixed-method study will evaluate the feasibility, preliminary efficacy, and user experience of a home-based wearable Focal Vibration Therapy (FVT) intervention for improving upper extremity (UEx) function in people…
- Trial name
- NCT07376772
- Testing
- wearable focal vibration therapy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- REAL-MS (NCT07899502)
- Testing
- Autologous haematopoietic stem cell transplantation (AHSCT), High-efficacy disease-modifying therapy (HE-DMT)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Multiple Sclerosis
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
- Trial name
- TRANSPLANTPRO (NCT06267781)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
- Trial name
- HERMOSA-2 (NCT07304154)
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 57 people
- Sponsor
- Kite, A Gilead Company